Good Economics for Hard Times is for voters, students, and policy readers who want what the evidence actually says on trade, immigration, welfare, and climate—not slogans from either side.
AbbVie paid $100 million upfront to license NXE0033744, an oral gut-restricted EP4 agonist from Nxera Pharma that targets a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results